Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia

Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, there is urgent demand for low-toxic palliative alternatives. We have repositioned two commonly administered anti-leukaemia drugs, valproic...

Descripción completa

Detalles Bibliográficos
Autores principales: Leitch, Calum, Osdal, Tereza, Andresen, Vibeke, Molland, Maren, Kristiansen, Silje, Nguyen, Xuan Nhi, Bruserud, Øystein, Gjertsen, Bjørn Tore, McCormack, Emmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884979/
https://www.ncbi.nlm.nih.gov/pubmed/26812881
http://dx.doi.org/10.18632/oncotarget.6991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884979/
https://www.ncbi.nlm.nih.gov/pubmed/26812881
http://dx.doi.org/10.18632/oncotarget.6991

Ejemplares similares